Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DVT Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery

NCT04305756
View directory record Official record
Conditions
Thromboembolism, Postpartum DVT, Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 22, 2026, 5:56 PM EDT
Completed No phase listed Observational

Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty

NCT01984190
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Little Rock, Alaska • La Jolla, California • Menlo Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)

NCT04635839
View directory record Official record
Conditions
Pregnancy Related, Antepartum DVT
Interventions
Standard Dose of Unfractionated Heparin, Gestational Age-Based Dose of Unfractionated Heparin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection

NCT06652568
View directory record Official record
Conditions
Deep Vein Thrombosis, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
ThinkSono System
Device
Lead sponsor
ThinkSono, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 22, 2026, 5:56 PM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vasculaire Compression System Increases Flow Velocity in the Femoral Vein

NCT01240330
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Pneumatic Compression therapy
Device
Lead sponsor
Venous Health Systems, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Portola Valley, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 1 Interventional Results available

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

NCT00412464
View directory record Official record
Conditions
Thrombosis, Heparin-induced Thrombocytopenia
Interventions
Fondaparinux
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Not applicable Interventional Results available

Angel® Catheter Early Feasibility Clinical Study

NCT01847196
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 22, 2026, 5:56 PM EDT
Not listed Not applicable Interventional

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

NCT00484640
View directory record Official record
Conditions
Atrial Fibrillation, Deep Venous Thrombosis, Heart Valve Replacement, Pulmonary Embolism
Interventions
Coumadin
Drug
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
40 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Madison, Wisconsin • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Oct 22, 2026, 5:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients

NCT04252651
View directory record Official record
Conditions
Inflammatory Response, Multi Organ Failure, Nosocomial Infection, Deep Vein Thrombosis
Interventions
Blood Draw
Other
Lead sponsor
Joseph M. Still Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 22, 2026, 5:56 PM EDT
Active, not recruiting Not applicable Interventional Results available

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
8
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Improving Venous Thromboembolism Prophylaxis

NCT01304108
View directory record Official record
Conditions
Venous Thromboembolism, Delivery of Health Care, Quality Improvement
Interventions
VTE-P Tollgate, BLAZE Pop up, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
17 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Phase 4 Interventional Results available

Calf Deep Vein Thrombosis Treatment Trial

NCT03590743
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Apixaban, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Rochester, Minnesota • Eau Claire, Wisconsin • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 5:56 PM EDT
Terminated No phase listed Observational

Point of Care Ultrasound (US) Versus Detailed Radiology US for Deep Vein Thrombosis (DVT)

NCT01045759
View directory record Official record
Conditions
DEEP VEIN THROMBOSIS
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 22, 2026, 5:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection

NCT02123550
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Swanson Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 22, 2026, 5:56 PM EDT
Completed No phase listed Observational

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

NCT03115541
View directory record Official record
Conditions
Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

NCT00371683
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin + Placebo, Apixaban + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3,608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 22, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 22, 2026, 5:56 PM EDT